GlassScriptPhysician profile
Amber N Nelson
NPI 1841650561
$8,616.39
in general payments reported to CMS, 2019-2025
42 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,436 · 2022: $1,649 · 2023: $819 · 2024: $1,747 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,265 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.86 |
| Education | $266.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,490.06 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,254.66 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $628.65 | 2021-2025 | Cuvitru, Cinryze, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $563.90 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $504.19 | 2022-2025 | Xolair |
| Pfizer INC. | $446.81 | 2021-2025 | |
| Genzyme Corporation | $418.22 | 2022-2025 | |
| Csl Behring | $415.50 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Amgen INC. | $390.87 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $352.87 | 2022-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $274.54 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $245.68 | 2025 | Neffy |
| Pharming Healthcare, INC. | $207.51 | 2021-2025 | Ruconest |
| Organon LLC | $165.54 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $162.42 | 2021-2024 | Orladeyo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $130.40 | 2021-2025 | |
| Alk-Abello, INC | $102.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Gc Biopharma USA, INC. | $96.73 | 2024-2025 | Alyglo, Alyglo |
| Genentech, INC. | $87.91 | 2023 | Xolair |
| Grifols USA, LLC | $56.24 | 2021-2022 | |
| Kaleo, INC. | $53.16 | 2021-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.62 | 2021 | |
| Octapharma USA, INC. | $46.03 | 2022-2024 | Octagam Immune Globulin (Human) |
| Merck Sharp & Dohme LLC | $42.67 | 2021-2022 | |
| Leo Pharma INC. | $35.90 | 2025 | Adbry |
| Inspire Medical Systems, INC. | $25.58 | 2025 | Inspire |
| Novo Nordisk INC | $24.68 | 2021 | |
| Ionis Pharmaceuticals, INC. | $22.79 | 2025 | Dawnzera |
| Stryker Corporation | $21.71 | 2025 | Scopis Ent |
| Sanofi Pasteur INC. | $20.74 | 2023 | |
| Mylan Specialty L.P. | $20.42 | 2024 | Yupelri |
| Karl Storz Endoscopy-America | $19.71 | 2025 | |
| Dermavant Sciences, INC. | $19.44 | 2024 | Vtama |
| Abbvie INC. | $18.76 | 2022 | |
| Cycle Pharmaceuticals INC | $18.34 | 2025 | Sajazir |
| Siemens Medical Solutions USA, INC. | $17.49 | 2025 | Immulite 1000 Immunoassay System |
| Janssen Biotech, INC. | $15.26 | 2024 | Rybrevant |
| Philips North America LLC | $15.26 | 2023 | |
| Exact Sciences Corporation | $14.53 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $12.92 | 2023 | Ryaltris |
| Corium, LLC | $5.78 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.